Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 17/20 | 0.78 |
| ▸ | GABRB3 | P28472 | 17/20 | 0.78 |
| ▸ | GABRA5 | P31644 | 14/20 | 0.78 |
| ▸ | GABRA3 | P34903 | 12/20 | 0.78 |
| ▸ | GABRA2 | P47869 | 9/20 | 0.78 |
| ▸ | GABRA1 | P14867 | 9/20 | 0.78 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.78 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.78 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL637898 | 0.89 | GABRG2 (0.70) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| Hydrochloric Acid SCHEMBL4081656 | 0.88 | GABRG2 (0.74) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| Hydrochloric Acid SCHEMBL638037 | 0.88 | GABRG2 (0.74) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| SCHEMBL638718 | 0.88 | GABRG2 (1.00) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| Hydrochloric Acid SCHEMBL637329 | 0.87 | GABRG2 (0.71) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| SCHEMBL637279 | 0.86 | GABRG2 (0.71) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| SCHEMBL638140 | 0.85 | GABRG2 (0.72) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| Hydrochloric Acid SCHEMBL638452 | 0.85 | GABRG2 (0.70) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| Hydrochloric Acid SCHEMBL4159931 | 0.85 | GABRG2 (0.70) | GABRG2GABRB3GABRA5GABRA3GABRA2 | |
| SCHEMBL638697 | 0.85 | GABRG2 (0.71) | GABRG2GABRB3GABRA5GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093466-A1 | Carboxamide GABAa ALPHA2 Modulators | BRISTOL-MYERS SQUIBB COMPANY | 2009-04-09 | — | — | US | claimed |
| US-8119629-B2 | Carboxamide GABAA α2 modulators | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090093466-A1 | Carboxamide GABAa ALPHA2 Modulators | BRISTOL-MYERS SQUIBB COMPANY | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093466-A1 | Carboxamide GABAa ALPHA2 Modulators | GABRA2, GABRB2, GABRB1 | GABRG2 12/4885GABRB3 7/4885GABRA5 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.